Roche ends work on tominersen after decade of trials, as well as early-stage Huntington’s asset

Phase 2negativetominersenNegative

AI Analysis

Summary

Roche has discontinued tominersen for Huntington's disease after more than a decade of development following negative Phase 2 trial results showing no efficacy advantage over placebo. The company is also discontinuing an early-stage Huntington's asset as part of this strategic decision.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Not Met

Outcome Details

tominersen did no better than placebo in Phase 2 trial

Importance:7/10

Sentiment:

-0.95

program_discontinuationhuntingtons_diseasephase_2_failurefailed_trial

Related Companies

$RHHBY

Read the original article

Published by Endpoints News on July 9, 2026 6:17 PM

Read Original